EyePoint’s Duravyu falls short to Eylea in Phase III trial
EyePoint’s stock dropped 67% after its potential Eylea (aflibercept) competitor Duravyu fell short in a Phase III trial…
Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now. On…
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog.…